A new Kayvirus vB_SauM-MUHD-1 combats Methicillin-resistant Staphylococcus aureus wound infections

Résumé

Methicillin-resistant Staphylococcus aureus (MRSA), a leading cause of chronic and post-surgical wound infections, is a hard-to-treat pathogen. In this study, we isolated and characterized a lytic MRSA bacteriophage, vB_SauM-MUHD-1, and evaluated its therapeutic potential in a murine wound infection model. Among 107 clinical wound samples, MRSA was reported in 48.6% of cases. Phage vB_SauM-MUHD-1, isolated from sewage, demonstrated lytic activity against 70.6% of the tested MRSA isolates. The phage exhibited efficient replication kinetics and remained stable under physiologically relevant conditions. Whole-genome sequencing identified a ~ 134 kb dsDNA genome (~ 30.45% GC) lacking detectable lysogeny-associated, virulence, or antimicrobial-resistance genes. In a BALB/c excisional wound model infected with MRSA, topical phage treatment significantly reduced bacterial burden, accelerated wound closure, and improved clinical severity scores compared to untreated controls, performing comparably to phage-linezolid combination therapy and outperforming linezolid monotherapy in bacterial clearance. These findings support that our phage vB_SauM-MUHD-1 has potential for treating MRSA-infected wounds and should be further investigated for efficacy in more challenging chronic or biofilm-rich wound environments. KEY POINTS: • This study provides a newly kayvirus, strictly lytic anti-MRSA phage vB_SauM-MUHD-1. • Phage exhibited favorable replication kinetics, physical stability and genomic safety. • Topical phage therapy reduced bacterial burden and accelerated wound healing.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0